findmyKOL

Rodolfo Galindo, MD

Enriched profile

Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism · Leonard M. Miller School of Medicine

ORCID↗NPI↗
✓ Full profile
Region🇺🇸 Pembroke Pines, FL · Southeast · United StatesSpecialtyEndocrinology, Diabetes & MetabolismFocusEndocrinology/Metabolic
Active KOLfindmyKOL type: EliteLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2023–2025

Rodolfo Galindo is Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism at Leonard M. Miller School of Medicine. OpenAlex indexes 214 publications with 6,829 citations (h-index 38); ClinicalTrials.gov lists 1 registered study with this person as an investigator.

Data verified 14 Aug 2026

Overview

Updated 16 Oct 2026

Rodolfo Galindo, MD, is Associate Professor of Medicine, Division of Endocrinology, Diabetes and Metabolism at Leonard M. Miller School of Medicine, University of Miami. The public record shows 214 publications with 6,829 citations (h-index 38), centered on Endocrinology/Metabolic. It also documents an investigator role on 1 registered clinical trials, industry payments reported by 16 companies, 2 NIH-funded awards (2023–2025).

  • Most recent indexed publication: 2026 · Diabetes care
  • Top research focus: Endocrinology/Metabolic
  • 1 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 16 companies

Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.

Research focus

OpenAlex concept fingerprint
Endocrinology/Metabolic

Drugs & molecules

across trials, industry payments and publications
Mounjarogeneric · TirzepatideClinical trials—Industry payments28Publications4Wegovygeneric · SemaglutideClinical trials—Industry payments5Publications1Jardiancegeneric · EmpagliflozinClinical trials—Industry payments6Publications—Tresibageneric · Insulin degludecClinical trials—Industry payments6Publications—SOLIQUA 100Clinical trials—Industry payments5Publications—Kerendiageneric · FinerenoneClinical trials—Industry payments4Publications—Tzieldgeneric · TeplizumabClinical trials—Industry payments3Publications—Humaloggeneric · Insulin lisproClinical trials—Industry payments1Publications—Tepezzageneric · TeprotumumabClinical trials—Industry payments1Publications—Toujeogeneric · Insulin glargineClinical trials—Industry payments1Publications—Tradjentageneric · LinagliptinClinical trials—Industry payments1Publications—Xareltogeneric · RivaroxabanClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Eli Lilly and CompanyClinical trials—Industry payments42Lilly USA, LLCClinical trials—Industry payments30Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trials—Industry payments22Novo Nordisk IncClinical trials—Industry payments22Bayer HealthCare Pharmaceuticals Inc.Clinical trials—Industry payments20Medtronic, Inc.Clinical trials—Industry payments12Sanofi-Aventis U.S. LLCClinical trials—Industry payments10Dexcom, Inc.Clinical trials—Industry payments9Abbott LaboratoriesClinical trials—Industry payments5Amgen Inc.Clinical trials—Industry payments2Boehringer Ingelheim Mexico SA de CVClinical trials—Industry payments2Emory UniversityClinical trials1Industry payments—Janssen Scientific Affairs, LLCClinical trials—Industry payments1Pfizer Inc.Clinical trials—Industry payments1Sequel Med Tech, LLCClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
214publications

Distinct works indexed by OpenAlex, matched via ORCID; 64 in PubMed.

6,829citations

Total citations across indexed works.

38h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
1clinical trials

Investigator role on registered studies.

View trials ↓
16companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
2NIH grants · 2023–2025

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 16 Oct 2026

Listed as an investigator on 1 registered study on ClinicalTrials.gov. The most recent:

Industry payments

Updated 16 Oct 2026

16 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Metabolism & gastrointestinal

    63.8%
    GLP-1 receptor agonist63.8%
    Mounjaro75%Ozempic25%
    Part D<11 patients
  • Hormonal (systemic)

    18.8%
    l-Thyroxine18.8%
    Levothyroxine Sodium100%
    Part D<11 patients
  • Genitourinary & hormones

    17.4%
    Androgen17.4%
    Xyosted100%
    Part D<11 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 16 Oct 2026

2 NIH research awards on record, funded 2023–2025 per NIH RePORTER. The latest:

Publications

Updated 16 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 16 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • Doximity

    doximity.com/pub/rodolfo-galindo-md

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗

Mentions by others

where others cite or feature them
  • LinkedIn

    LinkedIn: "Rodolfo Galindo - University of Miami" (auth-walled, corroborated by SERP snippet)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
  • ResearchGate

    ResearchGate: "Rodolfo GALINDO | Professor (Associate) | University of Miami, Coral Gables | Endocrinology, Diabetes and Metabolism Division"

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
  • Doximity

    Doximity: "Dr. Rodolfo Galindo, MD – Miami, FL | Endocrinology"

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 16 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Author/member

    ADA Standards of Care for Diabetes guideline committee

    2025
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practicingclinicians.com ↗
  • Author/member

    AACE Diabetes Mellitus Comprehensive Care Plan (2022) and AACE Type 2 Diabetes Management Algorithm

    2023
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →practicingclinicians.com ↗
  • Director

    Comprehensive Diabetes Center, UHealth (University of Miami Health System)

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →diabetesresearch.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.